UP TO USD 1 MILLION AVAILABLE TO FUND YOUR INNOVATIVE PROJECT IN TB CASE FINDING AND TREATMENT
Deadline for applications is 2nd April.
The Stop TB Partnership’s TB REACH is looking to fund organizations that combine ground-breaking ideas in TB case finding and treatment with the empowerment of women & girls, but time is running out! The deadline for applications is 2nd April at 17:00 (Geneva time). To date, TB REACH has funded projects in over 50 countries, with more than 2 million people being diagnosed with TB. Help us #EndTB by submitting your proposal now!
The Stop TB Partnership is proud to support the Government of Canada’s Feminist International Assistance Policy
For more details click on the link : https://globalfundkcm.or.ke/news/
Through the partnership with Global fund over 226,508 tuberculosis patients have been
provided with anti TB treatment since 2015. Kenya recently completed TB prevalence survey
to establish the true burden of TB in Kenya and to measure the progress made in TB control.
The results of the survey showed that the burden still remain high with prevalence of 558 per
100,000 and incidence of about 169,000 annually. The Global Fund Grant has enabled
Provision of second line treatment to about 1186 drug resistance tuberculosis cases in the last
3 years including patient support and enrolling patients to NHIF Scheme. New technologies
to aid in diagnosis of TB have been rolled out and Kenya has now close to 200 gene Xpert
machines installed in various health facilities in Counties and National Level.
Brief on the HIV Global Fund Round 10 proposal
In the past Kenya received Global Fund HIV grants from Rounds 1 and 2 which were fully implemented. In 2009 Kenya received the Round 7 grant which is currently being implemented. The Round 8 proposal was rejected as was the National Strategy Application of the First Learning Wave (NSA FLW)/Round 9. The HIV Round 10 proposal was recommended for funding (as a Category 2b conditional upon addressing the weaknesses mentioned to the satisfaction of the TRP during the clarification process.)
Kenya has severe, generalized HIV epidemic, but in recent years, the country has experienced a notable decline in HIV prevalence, attributed in part to significant behavioral change and increased access to ART (antiretroviral drugs).
Kenya has been a pioneer in numerous global health innovations – from self-test kits and pre-exposure prophylaxis (PrEP) to malaria vaccine and child-friendly TB medicines. The country has had great success in putting people on HIV treatment, hitting the 1 million mark in 2017, up from 98,000 in 2006.
Strong community-based work, including the empowerment of women coupled with a strong partnership between Kenya and international partners, has helped bolster the response to HIV, tuberculosis and malaria. Devolution of management of health from the national to the local level since 2013 promises to transform the way health care is managed and delivered in the country.
Despite that progress, Kenya still faces challenges in the response to HIV, TB and malaria, and in building resilient and sustainable systems for health. With 1.5 million people living with HIV in the country, Kenya has the fourth-largest HIV epidemic in the world. At about 78,000, the number of new HIV infections per year remains high. As for TB, the country is one of the 30 high-burden countries that together account for more than 80 percent of the world’s TB cases. Drug-resistant TB remains a big challenge in the country. Malaria remains a major cause of sickness and death, with more than 70 percent of the population at risk of the disease.